PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) Operating Margin
- Operating margin · 12 months: Value -101.80%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -101.80% | Operating income / revenue. Period ending 2026-06-30. $-55.51M ÷ $54.53M × 100 ≈ -101.80% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -55.51M USD | Operating Income (Loss) |
| Revenue | 54.53M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 64.95M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-55.51M | $54.53M | (m) | $64.95M | (m) | -101.80% |
| 2026-03-31 | $-119.02M | $57.94M | (m) | $96.67M | (m) | -205.43% |
| 2025-12-31 | $-214.64M | $9.68M | (m) | $134.85M | (m) | -2216.44% |
| 2025-09-30 | $-255.33M | $11.79M | (m) | $170.44M | (m) | -2166.42% |
| 2025-06-30 | $-281.61M | $10.34M | (m) | $192.22M | (m) | -2723.21% |
| 2025-03-31 | $-138.61M | $137.94M | (m) | $209.22M | (m) | -100.49% |
| 2024-12-31 | $-154.56M | $135.16M | (m) | $222.52M | (m) | -114.36% |
| 2024-09-30 | $-168.18M | $133.35M | (m) | $234.24M | (m) | -126.12% |
| 2024-06-30 | $-91.36M | $217.25M | (m) | $241.43M | (m) | -42.05% |
| 2024-03-31 | $-216.24M | $89.25M | (m) | $239.93M | (m) | -242.28% |
| 2023-12-31 | $-191.04M | $91.37M | (m) | $220.57M | (m) | -209.08% |
| 2023-09-30 | $-112.59M | $140.98M | (m) | $195.55M | (m) | -79.87% |
| 2023-06-30 | $-173.23M | $57.63M | (m) | $177.50M | (m) | -300.61% |
| 2023-03-31 | $-149.94M | $54.92M | (m) | $153.06M | (m) | -273.01% |
| 2022-12-31 | $-131.56M | $53.91M | (m) | $135.56M | (m) | -244.05% |
| 2022-09-30 | $-164.58M | $5.15M | (m) | $120.75M | (m) | -3193.19% |
| 2022-06-30 | $-5.02M | $142.81M | (m) | $98.88M | (m) | -3.51% |
| 2022-03-31 | $66.14M | $201.57M | (m) | $88.40M | (m) | 32.81% |
| 2021-12-31 | $71.97M | $200.58M | (m) | $82.28M | (m) | 35.88% |
| 2021-09-30 | $74.76M | $199.76M | (m) | $80.99M | (m) | 37.42% |
| 2021-06-30 | $-65.31M | $60.75M | (m) | $84.60M | (m) | -107.52% |
| 2021-03-31 | $-120.00M | $872.00K | (m) | $80.78M | (m) | -13760.89% |
| 2020-12-31 | $-112.73M | $853.00K | (m) | $74.88M | (m) | -13216.18% |
| 2020-09-30 | $-105.70M | $749.00K | (m) | $69.59M | (m) | -14112.15% |
| 2020-06-30 | $-95.83M | $797.00K | (m) | $60.48M | (m) | -12023.34% |
| 2020-03-31 | $-87.59M | $769.00K | (m) | $52.79M | (m) | -11390.25% |
| 2019-12-31 | $-85.70M | $814.00K | (m) | $50.84M | (m) | -10527.89% |
| 2019-09-30 | $-85.18M | $752.00K | (m) | $51.88M | (m) | -11326.86% |
| 2019-06-30 | $-88.53M | $802.00K | (m) | $57.90M | (m) | -11038.53% |
| 2019-03-31 | $-133.10M | $914.00K | (m) | $79.77M | (m) | -14562.47% |
| 2018-12-31 | $-158.85M | $955.00K | (m) | $101.18M | (m) | -16634.03% |
| 2018-09-30 | $-183.42M | $990.00K | (m) | $118.17M | (m) | -18526.97% |
| 2018-06-30 | $-212.63M | $954.00K | (m) | $140.97M | (m) | -22288.05% |
| 2018-03-31 | $-167.69M | $27.49M | (m) | $143.56M | (m) | -610.07% |
| 2017-12-31 | $-155.25M | $27.52M | (m) | $134.55M | (m) | -564.17% |
| 2017-09-30 | $-157.21M | $27.46M | (m) | $140.89M | (m) | -572.50% |
| 2017-06-30 | $-146.37M | $27.53M | (m) | $126.41M | (m) | -531.71% |
| 2017-03-31 | $-168.40M | $1.05M | (m) | $124.74M | (m) | -16053.00% |
| 2016-12-31 | $-159.53M | $1.05M | (m) | $119.53M | (m) | -15121.80% |
| 2016-09-30 | $-134.47M | $1.19M | (m) | $97.58M | (m) | -11290.51% |
| 2016-06-30 | $-114.44M | $1.33M | (m) | $87.93M | (m) | -8578.94% |
| 2016-03-31 | $-92.32M | $1.28M | (m) | $68.36M | (m) | -7217.98% |
| 2015-12-31 | $-79.94M | $1.61M | (m) | $58.44M | (m) | -4974.30% |
| 2015-09-30 | $-68.83M | $3.31M | (m) | $50.66M | (m) | -2077.57% |
| 2015-06-30 | $-59.30M | $4.37M | (m) | $43.86M | (m) | -1357.00% |
| 2015-03-31 | $-39.70M | $19.21M | (m) | $39.68M | (m) | -206.62% |
| 2014-12-31 | $-6.65M | $50.85M | (m) | $38.45M | (m) | -13.07% |
| 2014-09-30 | $-4.25M | (m) | (m) | $33.95M | (m) | (m) |
| 2014-06-30 | $-680.00K | (m) | (m) | $29.91M | (m) | (m) |
| 2014-03-31 | $-13.44M | (m) | (m) | $29.44M | (m) | (m) |
| 2013-12-31 | $-40.43M | (m) | (m) | $26.05M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-41.41M | (m) | (m) | $34.14M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-29.24M | (m) | (m) | $24.17M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |